Fingolimod (FTY720) HCl

Name: Fingolimod (FTY720) HCl
Brand: Selleck Chemicals
SKU: S5002
Rating: 5 (78 reviews)

For research use only.

Catalog No.S5002

78 publications

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Selleck's Fingolimod (FTY720) HCl has been cited by 78 publications

Nature, 2020, 24

PubMed: 32581358 ( click the link to review the publication )

Cancer Cell, 2019, 35(6):901-915

PubMed: 31185213 ( click the link to review the publication )

Int J Med Sci, 2021, 18(2):304-313

PubMed: 33390799 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2021, 49(1):83-95

PubMed: 33438446 ( click the link to review the publication )

Genome Biol, 2020, 21(1):269

PubMed: 33143730 ( click the link to review the publication )

Cancer Lett, 2020, 468:1-13

PubMed: 31593801 ( click the link to review the publication )

Front Immunol, 2020, 8;11:635

PubMed: 32322257 ( click the link to review the publication )

Front Immunol, 2020, 11:178

PubMed: 32194542 ( click the link to review the publication )

Antiviral Res, 2020, S0166-3542(20)30413-7

PubMed: 33346055 ( click the link to review the publication )

J Biol Chem, 2020, 10.1074/jbc.RA119.011265

PubMed: 32071079 ( click the link to review the publication )

Immunol Cell Biol, 2020, 10.1111/imcb.12400

PubMed: 32893406 ( click the link to review the publication )

Phytother Res, 2020, 10.1002/ptr.6968

PubMed: 33274566 ( click the link to review the publication )

Transl Oncol, 2020, 14(1):100926

PubMed: 33157518 ( click the link to review the publication )

Am J Nephrol, 2020, 51(1):1-10

PubMed: 31694015 ( click the link to review the publication )

Neuromolecular Med, 2020, 22(2):218-226

PubMed: 31664682 ( click the link to review the publication )

Blood Adv, 2020, 4(12):2595-2605

PubMed: 32544236 ( click the link to review the publication )

Mucosal Immunol, 2020, 13(1):172-182

PubMed: 31659300 ( click the link to review the publication )

Mucosal Immunol, 2020, 10.1038/s41385-020-0327-1

PubMed: 32719409 ( click the link to review the publication )

Sci Immunol, 2019, 4(38)

PubMed: 31399492 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30775969 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.229351

PubMed: 31653711 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):289-300

PubMed: 30482853 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7771

PubMed: 31123291 ( click the link to review the publication )

Int Immunopharmacol, 2019, 66:224-235

PubMed: 30476824 ( click the link to review the publication )
PLoS One, 2019, 14(4):e0214469

PubMed: 30969990 ( click the link to review the publication )

Neurotherapeutics, 2019, 16(3):808-827

PubMed: 30815844 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0577-7

PubMed: 31636343 ( click the link to review the publication )

Theranostics, 2018, 8(14):3824-3840

PubMed: 30083262 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(2):785-800

PubMed: 30032136 ( click the link to review the publication )

J Immunol, 2018, 200(9):3100-3108

PubMed: 29563179 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29618748 ( click the link to review the publication )

Immunobiology, 2018, 223(11):634-647

PubMed: 30005970 ( click the link to review the publication )

Neuropharmacology, 2017, 119:1-14

PubMed: 28373076 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29113071 ( click the link to review the publication )

Breast Cancer Res Treat, 2017, 165(3):531-543

PubMed: 28695300 ( click the link to review the publication )

Cytokine, 2017, 90:73-79

PubMed: 27816795 ( click the link to review the publication )

Acta Haematol, 2017, 137(1):1-6

PubMed: 27802432 ( click the link to review the publication )

Pharmacol Res Perspect, 2017, 5(3):e00308

PubMed: 28480040 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 31;4:28

PubMed: 27036416 ( click the link to review the publication )

Eur J Immunol, 2016, 46(12):2730-2736

PubMed: 27730626 ( click the link to review the publication )

Cell Mol Neurobiol, 2016, 36(1):131-42

PubMed: 26099903 ( click the link to review the publication )

Immunity, 2015, 43(5):1011-21

PubMed: 26588783 ( click the link to review the publication )

Leukemia, 2015, 29(4):847-57

PubMed: 25306901 ( click the link to review the publication )

Brain Behav Immun, 2015, 50:78-86

PubMed: 26130058 ( click the link to review the publication )

J Biomed Nanotechnol, 2015, 11(4):691-701

PubMed: 26310075 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Mol Cell Endocrinol, 2015, 404:113-22

PubMed: 25643979 ( click the link to review the publication )
Chem-bio Interact, 2015, 10.1016/j.cbi.2015.05.006

PubMed: 25980589 ( click the link to review the publication )

Toxicol Lett, 2015,

PubMed: 25939952 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124510

PubMed: 25915660 ( click the link to review the publication )

J Exp Med, 2015, 212(13):2213-22

PubMed: 26573295 ( click the link to review the publication )

Am J Clin Exp Obstet Gynecol, 2015, 2(1):24-33

PubMed: ( click the link to review the publication )

Ann Neurol, 2014, 76(3):325-37

PubMed: 25043204 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(31):11515-20

PubMed: 25049382 ( click the link to review the publication )

Arch Toxicol, 2014, 88(3):673-89

PubMed: 24356939 ( click the link to review the publication )

J Immunol, 2014, 192(11):5151-9

PubMed: 24771853 ( click the link to review the publication )

Arthritis Res Ther, 2014, 16(4):R142

PubMed: 25000985 ( click the link to review the publication )

Acta Pharmacol Sin, 2014, 35(12):1537-45

PubMed: 25399649 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(6):797-805

PubMed: 24657936 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

BMC Cancer, 2014, 14:783

PubMed: 25344679 ( click the link to review the publication )

PLoS One, 2014, 9(7):e103033

PubMed: 25050888 ( click the link to review the publication )

Tumour Biol, 2014, 35(11):10707-14

PubMed: 25070489 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2250-61

PubMed: 24621013 ( click the link to review the publication )

J Lipid Res, 2013, 54(6):1616-29

PubMed: 23468130 ( click the link to review the publication )

Toxicol Sci, 2013, 135(2):328-46

PubMed: 23824090 ( click the link to review the publication )

PLoS One, 2013, 8(7): e70124

PubMed: 23936150 ( click the link to review the publication )

J Mol Histol, 2013, 44(6):693-703

PubMed: 23907620 ( click the link to review the publication )

Cancer Invest, 2013, 31(2):145-55

PubMed: 23362952 ( click the link to review the publication )

Ren Fail, 2013, 35(7):996-1004

PubMed: 23848241 ( click the link to review the publication )

Transplant Proc, 2013, 45(2):783-6

PubMed: 23498820 ( click the link to review the publication )
Blood, 2012, 119(9):2176-7

PubMed: 22383793 ( click the link to review the publication )

PLoS One, 2012, 7(5):e36429

PubMed: 22570713 ( click the link to review the publication )

PLoS One, 2012, 7(2):e32211

PubMed: 22359671 ( click the link to review the publication )

Int J Immunopathol Pharmacol, 2012, 25(2):397-406

PubMed: 22697071 ( click the link to review the publication )

Mol Med, 2011, 17(7-8):717-25

PubMed: 21556483 ( click the link to review the publication )

Dig Dis Sci, 2011, 56(8):2283-91

PubMed: 21374065 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Biological Activity

Description

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Targets

S1P receptor ^[1]
(K562, NK cells )

0.033 nM

In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. ^[1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human U2OS cells	NWDHV2pFTnWwY4Tpc44h[XO\|YYm=			MXLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGOxVFEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BmT0[SIHHzd4V{e2WmIHHzJJJm[2WydH;yJIlvfGW{bnHsbZpifGmxbjDpcpRwKGO7dH;wcIF{dSC3c3nu[{BJd2WlaIP0JIR6\SC\|dHHpcolv\yxiRVO1NF0xNjByMjFOwG0v	NXrQS3R5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNFQyPDRpPkKyNVA1OTR2PD;hQi=>
human PC3 cells	M{HWb2N6fG:2b4jpZ:Kh[XO\|YYm=		M4XOUlczKGh?	M1:xNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYOsJGlEPTB;OT64JO69VS5?	NUTVTGZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human NALM6 cells	M17PfmN6fG:2b4jpZ:Kh[XO\|YYm=		M2jSNFczKGh?	Ml7LR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hVkGOTU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPiEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N\|I9N2F-
human CCRF-CEM cells	NF3reVJEgXSxdH;4bYPDqGG\|c3H5		NHXNeHE4OiCq	NXrpdHFpS3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uPEDPxE1w	MnXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N\|IoRjJ2MkezOlMzRC:jPh?=
human SUP-B15 cells	MlPJR5l1d3SxeHnjxsBie3OjeR?=		MWW3NkBp	MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2yb4PpeIl3\SCqdX3hckBUXVBvQkG1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF03NjhizszNMi=>	NUPuWWhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human DU145 cells	NUjXc4pbS3m2b4TvfIlkyqCjc4PhfS=>		NGTjUoY4OiCq	NHv4U\|hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9Ok42KM7:TT6=	NHLWPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N\|Y{Oid-MkSyO\|M3OzJ:L3G+
human BV173 cells	M4nsUmN6fG:2b4jpZ:Kh[XO\|YYm=		MUi3NkBp	M4TSRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLYDvd4l1cX[nIHj1cYFvKEKYMUezJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF03NjNizszNMi=>	M{[3WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N\|Y{OjxxYU6=
human BLIN-1 cells	M3X1VmN6fG:2b4jpZ:Kh[XO\|YYm=		NFrCRW84OiCq	MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBDVEmQLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVUvPSEQvF2u	NGHCPFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N\|Y{Oid-MkSyO\|M3OzJ:L3G+
mouse bone marrow cells	MlLER5l1d3SxeHnjxsBie3OjeR?=		Mm\0O\|IhcA>?	NF25UmlEgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2KtRWJNKG[3c3nvckBxem:2ZXnuJFE6OCCneIDy[ZN{cW6pIH3veZNmKGKxbnWgcYFzem:5IHPlcIx{KGGodHXyJFczKGi{czDifUB3cXSjbDDkfYUh\XilbIXzbY9vN2[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME2zMlMh\|ryPLh?=	M1jRUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N\|Y{OjxxYU6=
Sf9 insect cells	MUfGeY5kfGmxbjDhd5NigQ>?		NILpcXoyKGh?	NUX4epRmUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTNXBNKCh4MjD0c{A2PjhrIHX4dJJme3OnZDDpckBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIGOxVEBieyC\|dXLzeJJifGViYX\0[ZIhOSCqch?=	NHThemo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwPVgyPCd-MkS4NFk5OTR:L3G+
mouse MN9D cells	MkDXSpVv[3Srb36gZZN{[Xl?	NVv4[20xPSEQvF2=		MVvJcoR2[3Srb36gc4YhWFB{QTDjZZRidHm2aXOgd5VjfW6rdDDhZ5Rqfmm2eTDpckBud3W\|ZTDNUllFKGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXN	NYPCVFRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
rat PC12 cells	Mkf1SpVv[3Srb36gZZN{[Xl?	MXy1JO69VQ>?	MX6zNEB1dyBzMkCgcYlvew>?	NH\3UIZKdmS3Y4Tpc44hd2ZiUGCyRUBk[XSjbIn0bYMhe3WkdX7peEBi[3Srdnn0fUBqdiC{YYSgVGMyOiClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhifGVibHX2[Ywh[XRiNTD1UUBu\WG\|dYLl[EA{OCC2bzCxNlAhdWmwcz6=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MEG2OUc,OjVyNUCxOlU9N2F-
mouse MN9D cells	MW\GeY5kfGmxbjDhd5NigQ>?	MYWwMlE3KM7:TR?=	MnHJNlQhcA>?	MV7O[ZVzd3C{b4TlZ5RqfmViYXP0bZZqfHliaX6gcY92e2ViTV65SEBk\WyuczDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDCSG5HKGW6cILld5Nqd25iYYSgNE4yPiC3TTDh[pRmeiB{NDDodpM>	NFLQUHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
mouse MN9D cells	NXPB[FZKTnWwY4Tpc44h[XO\|YYm=	M3XBVlAvOTZizszN	MmS1O\|IhcA>?	NYPtcY8yVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO\|ZYPz[YQh[XNiYnzvZ4tqdmdib3[gWG5HNWGucHjhJIF{e2:laXH0[YQhfG:6aXPpeJkh[XRiMD6xOkB2VSCjZoTldkA4OiCqcoOgZpkhXHK7cHHuJIJtfWVic4ThbY5qdmdw	NGe1foc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
CHO	MYjGeY5kfGmxbjDhd5NigQ>?			MmHESIl{eGyjY3Xt[Y51KG:oIGuzN3Bee3CqaX7nc5NqdmViMTDwbI9{eGijdHWg[pJwdSCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9NE45PM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZzNUWxN{c,OTV4MUW1NVM9N2F-
CHO	M175[WZ2dmO2aX;uJIF{e2G7			MoHrSIl{eGyjY3Xt[Y51KG:oIGuzN3Bee3CqaX7nc5NqdmViMTDwbI9{eGijdHWg[pJwdSCqdX3hckBUOVB3IILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9Nk4y\|ryPLh?=	NGS2O\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
Jurkat	NHOzOnpHfW6ldHnvckBie3OjeR?=		MoTHNVghcHK\|	MWDS[ZZmenOjbDDv[kBqdmirYnn0bY9vKG:oIH3peI9kcG:wZILpZYwh\nWwY4Tpc44hcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHmeIVzKDF6IHjyd{BqdiCycnXz[Y5k\SCxZjDaMXZCTC2obXu=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRyMEW1OUc,OTd2MEC1OVU9N2F-
T-cells	MoLGSpVv[3Srb36gZZN{[Xl?		MXS5OkBpenN?	M{HNWGludXWwb4P1dJBz\XO\|aY\lJIFkfGm4aYT5JIlvKEKDTFKvZ{9EPTeETD:2JI1wfXOnIGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHzvZY51cWenbj3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB7NjDodpMh[nlibXXhd5VzcW6pIGuzTH11cHmvaXTpcoUhfXC2YXvlJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44h[XO\|YYmsJGlEPTB;MD6wNFYy\|ryPLh?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SK-BR-3	NX;oOVYxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVfjbo9lPzhiaILz	M4DiR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utRnIuOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6=	M4f2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MDA-MB-231	NEjmfHdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2TVZlc5KGi{cx?=	NFLYXlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyPUZOwG0v	NYLIN3JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
HCT116	NX;uVG5tSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmT5O\|ghcHK\|	MlHYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|ghcHK\|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w	M1faZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
SW620	NVLFVJU3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUe3PEBpenN?	NGm5SZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOlIxKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02\|ryPLh?=	NETYSJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
MCF7	MormRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mmq1O\|ghcHK\|	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG\|c3H5MEBKSzVyPUZOwG0v	NH\kR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
LNCAP-AI	M{LLWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVy3PEBpenN?	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCOTlPBVE1CUSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6=	NF7JPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
MGC803	MYHBcpRqfHWvb4KgZZN{[Xl?	MYmxNEBu\y:tZx?=	MVeyNEBl[Xm\|	M3rMOWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HR\|gxOyClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IEGwJI1oN2upIH\vdkAzOCCmYYnz	M{HrflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
U2OS	MlPNSpVv[3Srb36gZZN{[Xl?		NX\DXG9wOThiaILz	MmOzRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXAyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDFSGcyNWKuYTDVNm9UKGOnbHzzJIlv[3WkYYTl[EBnd3JiMUigbJJ{KHC{aX;yJJRwKEenblLsZZpmeiC\|dXLzeJJifGViYXTkbZRqd25iYomgZoV1[S2jcoLld5RqdiC{ZXPyeYl1dWWwdDDhd5NigSxiRVO1NF0xNjByN{NOwG0v	M4jxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Nki3OFg4Lz5{Nk[4O\|Q5PzxxYU6=
FL5.12A	MonUR5l1d3SxeHnjbZR6KGG\|c3H5		NFXnZ5Q1QCCqcoO=	MoCzR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{QTDj[YxteyCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9Nk41\|ryPLh?=	MoXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{W1N\|QoRjJ5NEe1OVM1RC:jPh?=
SH-SY5Y	M334TmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVSyOEBpenN?	NFjlW5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjV2zszNMi=>	NWjsU\|hPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SK-N-SH	NGLmO5BEgXSxdH;4bYNqfHliYYPzZZk>		NF62bmozPCCqcoO=	NGTZUIdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy\|IH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSClconzeIFtNX[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiRVOxNF0xNjV3zszNMi=>	NYfrNpBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
U118MG	NIHNPHJEgXSxdH;4bYNqfHliYYPzZZk>		MUOyOEBpenN?	NIf5RphEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOTF6TVegZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPjIQvF2u	NEPLZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN\|EyPSd-Mke5NVMyOTV:L3G+
SH-SY5Y	NVf3d2c3TnWwY4Tpc44h[XO\|YYm=			MXnB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
U118MG	MWPGeY5kfGmxbjDhd5NigQ>?			MWXB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGWxNVhOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjRW1RKGyndnXsJIF1KEWFMUCgZpkh\Gm{ZXP0JIludXWwb3Hzd4F6	NES5TZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN\|EyPSd-Mke5NVMyOTV:L3G+
SK-N-SH	NGjXVXJHfW6ldHnvckBie3OjeR?=			MUHB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHj1cYFvKFONLV6tV2gh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY1HNVEBt\X[nbDDheEBGSzFyIHL5JIRqemWldDDpcY12dm:jc4PhfS=>	NWnFd5M6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
HEK293	MXfGeY5kfGmxbjDhd5NigQ>?		MmXJNVghcHK\|	NHTuSmFC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClQV3QJIxmfmWuIHH0JGVEOTBiYX\0[ZIhOThiaILzJIJ6KEOURT3y[ZNxd26\|aY\lJJJmdmmubHGgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	NF36SIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN\|EyPSd-Mke5NVMyOTV:L3G+
SJ-GBM2	NIrvNGFyUFSVIHHzd4F6			NFXORWVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NXj6e3FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MY\xTHRUKGG\|c3H5			NYP3bW9ieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MlrZdWhVWyCjc4PhfS=>			M{iwfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NFu5ZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NEDOenFyUFSVIHHzd4F6			NWnsOZI4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NYPucJBweUiWUzDhd5NigQ>?			NYLDSmlUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NUfyb2xIeUiWUzDhd5NigQ>?			NInFe5lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M2LpNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NWDidoxFeUiWUzDhd5NigQ>?			NXvkemZIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	NEnn[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NEfxboJyUFSVIHHzd4F6			NFXrbIdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	M2G4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	Mnm0dWhVWyCjc4PhfS=>			NEPUeGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	M4PlNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NECxR2FyUFSVIHHzd4F6			M4\TbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	M{PkUJFJXFNiYYPzZZk>			NH;IV4VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NXPpdW5wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NIrZb2tyUFSVIHHzd4F6			Ml\TdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NELETZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	M4Xl[JFJXFNiYYPzZZk>			Mn[5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MVLxTHRUKGG\|c3H5			MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M4jMNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MWDxTHRUKGG\|c3H5			NGmwc2pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	NGC1OYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NFv6OXdyUFSVIHHzd4F6			NHHt[YdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
FL5.12	M3\5XmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUXQUlc3PDhiaILz	NYPBSXBLS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJI9zKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTJwMd88UU4>	MoPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUK4PVgoRjNyMkmyPFk5RC:jPh?=
FL5.12	NVfxR3NsS3m2b4TvfIlkcXS7IHHzd4F6	NFPvR\|YyOCC3TR?=	NFTWUVI{KGi{cx?=	NEjB[4NEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{	NUjW[I55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVI5QThpPkOwNlkzQDl6PD;hQi=>
FL5.12	Ml;xR5l1d3SxeHnjbZR6KGG\|c3H5	NGXaUZMzNjVidV2=	NGHJNIU{KGi{cx?=	NWfkZ3EyS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyJINmdGy\|IHHzd4V{e2WmIHHzJJZi[3WxbHWg[o9zdWG2aX;uJIF1KDJwNTD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UhdWmlcn;zZ49xcWNiYX7hcJl{cXN?	NVHBZXFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVI5QThpPkOwNlkzQDl6PD;hQi=>
HepG2	M4jVU5FJXFNiYYPzZZk>			NXvp[3FNUGWyR{KgZ4VtdHNidnnhZoltcXS7IIHIWHMh\m:{IGrpb4Ehfmm{dYOgbY5pcWKrdH;ydy=>	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzN{Mkm1OFUoRjN\|MkK5OVQ2RC:jPh?=
CHO	NWPjWWNGTnWwY4Tpc44h[XO\|YYm=			NGPtdoZC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZYxkcXWvIH\seZgh[nliYXXxeY9zcW5vZHXybZZm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:Oi53MUG4Pe69VS5?	NHLlTok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OTR6NUSvK\|5EcEWPQly8M4E,
CHO	MlzWSpVv[3Srb36gZZN{[Xl?			NX;kb4ZGSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBUOVB3IILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ4Ft[2m3bTDmcJV5KGK7IHHldZVwemmwLXTldol3\WRibIXtbY5me2OnbnPlJIF{e2G7LDDFR\|UxRTNwMU[yNljPxE1w	NEGx[pk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OTR6NUSvK\|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin; PubMed: 28717222 Sci Rep Dose-dependent effects of FTY720 on the phosphorylation of Akt, mTOR, GSK3β, and IKKα/β, and the expression of NF-κB, and survivin in SCC2095 cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium for 24h, and cell lysates were immunoblotted as described in Material and Methods p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; PubMed: 25344679 BMC Cancer CC cells were treated for 24 h with or without FTY720 and analyzed for the indicated protein by western blotting. Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 ; PubMed: 25344679 BMC Cancer FTY720 induces expression of p16 and p27 and reduces expression of cyclin D1, CDK4, cyclin E and CDK2. CC cells were treated with FTY720 at the indicated concentrations for 24 h. Lysates were then prepared immediately and analyzed by western blotting for cyclin D1, CDK4, cyclin E, CDK2, p16 and p27. β-Actin was used as the internal control. All assays were done in triplicate.	28717222 25344679
Immunofluorescence	NF-κB; PubMed: 28717222 Sci Rep Effect of FTY720 on the nuclear translocation of NF-κB. SCC2095 cells were treated with 5μM FTY720 for 24h, stained with anti-NF-κB, and examined by confocal microscopy. N-cadherin / Vimentin ; PubMed: 25344679 BMC Cancer Single and merged images show immunofluorescence staining of N-cadherin (green) and vimentin (red). The cell nucleus is stained blue by DAPI.	28717222 25344679
Growth inhibition assay	Cell viability; PubMed: 28717222 Sci Rep Effect of FTY720 at the indicated concentrations on the viability of oral cancer cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium in 96- well plates at 24h, and cell viability was assessed by MTT assays. Points, means; bars, S.D. (n=6). *P<0.01 compared to the control group.	28717222

In vivo

FTY720 is effective in Ph⁺ but not Ph^- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph⁺ ALL xenografts using an early disease model. Ph⁺ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph^- ALL xenografts. ^[3]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: Immature DCs
Concentrations: 10 nM
Incubation Time: 4 hours
Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 10⁵ cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: NOD/SCIDγc^−/− mice bearing ALL cells.
Dosages: 5 mg/kg/day, 10 mg/kg/day
Administration: Administered via i.p.
(Only for Reference)

References

[4] Nikolova Z, et al. Transpl Immunol. 2001, 8(4), 267-277.

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (200.63 mM)
	Water	69 mg/mL (200.63 mM)
	Ethanol	'69 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Fingolimod (FTY720) HCl SDF

Molecular Weight	343.9
Formula	C₁₉H₃₃NO₂.HCl
CAS No.	162359-56-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03345940	Terminated	Drug: Fingolimod\|Drug: Dimethyl Fumarate	Relapsing Remitting Multiple Sclerosis	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta\|Patient-Centered Outcomes Research Institute\|Universita degli Studi di Genova	April 30 2017	Phase 4
NCT02575365	Terminated	Drug: 05 mg Fingolimod	Cognition\|Brain Volume Loss	Novartis Pharmaceuticals\|Novartis	February 16 2016	Phase 4
NCT02490930	Completed	Drug: Fingolimod	Glioblastoma\|Anaplastic Astrocytoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	July 2015	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

S1P Receptor Signaling Pathway Map

Related S1P Receptor Products

Siponimod (BAF312) ^New

BAF312 (Siponimod) is a next-generation S1P receptor agonist, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.
SB225002 ^New

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
Smoothened Agonist (SAG) HCl ^New

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
PF-543

PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and K_i of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. PF-543 induces apoptosis, necrosis, and autophagy.

Features:The most potent inhibitor of SphK1 described to date.
SKI II

SKI II (SphK-I2) is a highly selective and non ATP-competitive sphingosine kinase (SphK) inhibitor with IC50 of 0.5 μM, while exhibiting no inhibitory action on other kinases including PI3K, PKCα and ERK2.
Vismodegib (GDC-0449)

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
Colforsin (Forskolin)

Colforsin (Forskolin, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
Cyclopamine

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Plerixafor (AMD3100) 8HCl

Plerixafor (AMD3100, JM 3100) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
GANT61

GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Fingolimod (FTY720) HCl